Skip to main content
Clinical Trials/NCT03518996
NCT03518996
Withdrawn
Not Applicable

Non-Invasive Brain Stimulation and Delirium

Gen Shinozaki1 site in 1 countrySeptember 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mental Disorders
Sponsor
Gen Shinozaki
Locations
1
Primary Endpoint
Change in brain rhythms
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to examine whether non-invasive brain stimulation can be used to improve cognitive deficits in patients with delirium.

Detailed Description

Data from subject's EPIC medical record will be abstracted for use in research analysis - the following elements will be reviewed: Information regarding diagnosis, age, gender, ethnicity/race, medication they are receiving as well as their past medical history, and DOSS score. The study team member will also discuss patient's mental status with their treating clinician before approaching him/her. The treating clinician will be consulted and must agree that it is appropriate for the delirious patient to be approached for enrollment. Beforehand, a clinician on the research team (Dr. Gen Shinozaki) will evaluate the subjects ability to sign consent, and thus, whether they can be approached for enrollment. When subject is identified, consent team will approach to obtain consent (and assent when applicable), email address and research demographic information. If consented, subject undergo a short CAM-ICU assessment of delirium indication - the CAM-ICU is a delirium screening tool and is not done for screening individuals out of the study, a cognitive function evaluation (MoCA), Clinical Dementia Rating (CDR), and a longer delirium evaluation (DRS-R-98) conducted by a study team member. Next, study personnel will obtain buccal swab samples and will assist with saliva samples. Trained medical staff will perform the blood draw for the blood collection sample, approximately 5-10 mL of blood per sample will be collected. If consented, subject will be asked to wear non-invasive EEG device (with two standard, clinical leads) on their head at the time of initial evaluation and up to two times daily during their hospital stay. What subjects will be asked to do/what happens in the study (in sequential order) if they meet inclusion criteria and consent, they will be asked to wear non-invasive EEG device (with two standard, clinical leads) on their head with EEG monitor capability up to three times daily while they are in the hospital. One session of non-invasive brain stimulation will be administered. Study personnel will again obtain buccal swab samples and will assist with saliva samples. Trained research team members will perform the blood draw for the blood collection sample, approximately 5-10 mL of blood per sample will be collected.

Registry
clinicaltrials.gov
Start Date
September 1, 2018
End Date
December 1, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Gen Shinozaki
Responsible Party
Sponsor Investigator
Principal Investigator

Gen Shinozaki

Associate Professor of Psychiatry

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • A clinical diagnosis consistent with enrollment (positive for delirium)

Exclusion Criteria

  • History of recurrent seizures or epilepsy
  • Any other neurological or psychiatric diagnosis outside the diagnosis for which the participant is enrolled.
  • Active substance use disorder in the past 6 months other than tobacco use disorder.
  • Pacemaker
  • Coronary Stent
  • Defibrillator
  • Neurostimulation
  • Claustrophobia
  • Uncontrolled high blood pressure
  • Atrial fibrillation

Outcomes

Primary Outcomes

Change in brain rhythms

Time Frame: During the 1 week of treatment, with follow up 1 week

Change from baseline EEG activity in participants receiving stimulation

Secondary Outcomes

  • Delirium Observation Screening (DOS) Scale(During the 1 week of treatment, with follow up 1 week)
  • Delirium Rating Scale-R-98 (DRS)(During the 1 week of treatment, with follow up 1 week)
  • Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)(During the 1 week of treatment, with follow up 1 week)

Study Sites (1)

Loading locations...

Similar Trials